{
    "Clinical Trial ID": "NCT01631552",
    "Intervention": [
        "INTERVENTION 1: ",
        "  TNBC Target Population",
        "  Overall 144 participants with TNBC were enrolled in the study and received at least one dose of SG. Of these 144 participants, 108 received at least 2 prior therapies for metastatic disease and were treated with SG at a starting dose of 10mg/kg. These 108 participants were included in the analysis of safety and were referred to as the TNBC Target Population.",
        "INTERVENTION 2: ",
        "  HR+/HER2- mBC Population",
        "  Overall 68 participants with non-TNBC were enrolled in the study and received at least one dose of SG. Of these 68 participants, 54 were confirmed as Hormone receptor-positive/Human epidermal growth factor receptor 2-negative (HR+/HER2-), had progressed on at least one prior hormonal therapy in the metastatic setting, and had received at least one dose of 10 mg/kg SG. These 54 participants were included in the analysis of safety and were referred to as the HR+/HER2- mBC Population."
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Individuals able to understand and give written informed consent.",
        "  Histologically or cytologically confirmed epithelial cancer of one of the following types:",
        "  Gastric adenocarcinoma (GC)",
        "  Esophageal cancer (EC)",
        "  Hepatocellular carcinoma (HCC)",
        "  Non-small-cell lung cancer (NSCLC)",
        "  Small-cell lung cancer (SCLC)",
        "  Epithelial ovarian cancer (EOC)",
        "  Cervical Cancer",
        "  Endometrial Cancer",
        "  Triple-negative breast cancer (TNBC)",
        "  Non-triple-negative breast cancer",
        "  Papillary thyroid cancer (excludes follicular, medullary, Hurthle cell, and anaplastic thyroid cancer)",
        "  Glioblastoma multiforme (GBM)",
        "  Hormone-refractory prostate cancer (HRPC)",
        "  Head and neck cancers- squamous cell (SCCHN)",
        "  Renal cell cancer (clear cell) (RCC)",
        "  Urothelial cancer",
        "  Stage IV (metastatic) disease (except for individuals with GBM).",
        "  Refractory to or relapsed after at least one prior standard therapeutic regimen",
        "  Adequate performance status (ECOG 0 or 1)",
        "  Expected survival  6 months.",
        "  Measurable disease by CT or MRI.",
        "  At least 2 weeks beyond treatment (chemotherapy, investigational drugs including small molecular inhibitors, immunotherapy and/or radiation therapy) or major surgery and recovered from all acute toxicities to Grade 1 or less (except alopecia).",
        "  At least 2 weeks beyond high dose systemic corticosteroids (however, low dose corticosteroids < 20 mg prednisone or equivalent daily are permitted).",
        "  Adequate hematology without ongoing transfusional support (hemoglobin > 9 g/dL, absolute neutrophil count (ANC) > 1,500 per mm^3, platelets > 100,000 per mm^3).",
        "  Adequate renal and hepatic function (creatinine  2.0 x institutional upper limit of normal (IULN), bilirubin  1.5 IULN, aspartate aminotransferase (AST) and alanine aminotransferase (ALT)  3.0 x IULN or 5 x IULN if know liver metastases).",
        "  Otherwise, all toxicity at study entry  Grade 1.",
        "Exclusion Criteria:",
        "  Women who are pregnant or lactating.",
        "  Women of childbearing potential and fertile men unwilling to use effective contraception during study until conclusion of 12-week post-treatment evaluation period.",
        "  Individuals with Gilbert's disease.",
        "  Individuals with brain metastases can be enrolled only if treated, non-progressive brain metastases and off high-dose steroids (> 20 mg prednisone or equivalent) for at least 4 weeks.",
        "  Presence of bulky disease (defined as any single mass > 7 cm in its greatest dimension). Individuals with a mass over 7 cm, but otherwise eligible, may be considered for enrollment after discussion and approval with the medical monitor.",
        "  Individuals with active  grade 2 anorexia, nausea or vomiting, and/or signs of intestinal obstruction.",
        "  Individuals with non-melanoma skin cancer or carcinoma in situ of the cervix are eligible, while individuals with other prior malignancies must have had at least a 3-year disease-free interval.",
        "  Individuals known to be HIV positive, hepatitis B positive, or hepatitis C positive.",
        "  Known history of unstable angina, MI, or CHF present within 6 months or clinically significant cardiac arrhythmia (other than stable atrial fibrillation) requiring anti-arrhythmia therapy.",
        "  Known history of clinically significant active COPD, or other moderate-to-severe chronic respiratory illness present within 6 months.",
        "  Prior history of clinically significant bleeding, intestinal obstruction, or GI perforation within 6 months of initiation of study treatment.",
        "  Infection requiring intravenous antibiotic use within 1 week.",
        "  History of an anaphylactic reaction to irinotecan or  Grade 3 GI toxicity to prior irinotecan,",
        "  Other concurrent medical or psychiatric conditions that, in the Investigator's opinion, may be likely to confound study interpretation or prevent completion of study procedures and follow-up examinations."
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Percentage of Participants Experiencing Any Treatment Emergent Adverse Events and Serious Treatment Emergent Adverse Events",
        "  Treatment-emergent adverse events (TEAEs) were defined as any adverse events (AEs) that begin or worsen on or after the start of study drug through 30 days after the last dose of study drug. The severity was graded based on the National Cancer Institute's Common Terminology Criteria for Adverse Events Version 4.03. An AE that met one or more of the following outcomes was classified as serious:",
        "  Fatal",
        "  Life-threatening",
        "  Disabling/incapacitating",
        "  Results in hospitalization or prolongs a hospital stay",
        "  A congenital abnormality",
        "  Other important medical events may also be considered serious AEs if they may require medical or surgical intervention to prevent one of the outcomes listed above",
        "  Per planned analysis, populations to be used for evaluation of this outcome measure were as follows: Triple Negative Breast Cancer (TNBC) Target Population, HR+/HER2- Metastatic Breast Cancer (mBC) Population, Metastatic Urothelial Cancer (mUC) Population, and Overall Safety Population.",
        "  Time frame: First dose date up to last dose for data cutoff date of 01 March 2019 (maximum duration: 55.2 months) plus 30 days",
        "Results 1: ",
        "  Arm/Group Title: TNBC Target Population",
        "  Arm/Group Description: Overall 144 participants with TNBC were enrolled in the study and received at least one dose of SG. Of these 144 participants, 108 received at least 2 prior therapies for metastatic disease and were treated with SG at a starting dose of 10mg/kg. These 108 participants were included in the analysis of safety and were referred to as the TNBC Target Population.",
        "  Overall Number of Participants Analyzed: 108",
        "  Measure Type: Number",
        "  Unit of Measure: Percentage of participants  Adverse Events: 100.0",
        "  Serious Adverse Events: 30.6",
        "Results 2: ",
        "  Arm/Group Title: HR+/HER2- mBC Population",
        "  Arm/Group Description: Overall 68 participants with non-TNBC were enrolled in the study and received at least one dose of SG. Of these 68 participants, 54 were confirmed as Hormone receptor-positive/Human epidermal growth factor receptor 2-negative (HR+/HER2-), had progressed on at least one prior hormonal therapy in the metastatic setting, and had received at least one dose of 10 mg/kg SG. These 54 participants were included in the analysis of safety and were referred to as the HR+/HER2- mBC Population.",
        "  Overall Number of Participants Analyzed: 54",
        "  Measure Type: Number",
        "  Unit of Measure: Percentage of participants  Adverse Events: 100.0",
        "  Serious Adverse Events: 35.2"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 192/495 (38.79%)",
        "  Anaemia 4/495 (0.81%)",
        "  Febrile neutropenia 20/495 (4.04%)",
        "  Leukocytosis 1/495 (0.20%)",
        "  Leukopenia 1/495 (0.20%)",
        "  Lymphopenia 1/495 (0.20%)",
        "  Neutropenia 7/495 (1.41%)",
        "  Acute myocardial infarction 1/495 (0.20%)",
        "  Atrial fibrillation 3/495 (0.61%)",
        "  Cardiac tamponade 1/495 (0.20%)",
        "  Cardio-respiratory arrest 1/495 (0.20%)",
        "Adverse Events 2:",
        "   "
    ]
}